Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...
1d
Pharmaceutical Technology on MSNInsilico raises $110m to develop drug pipeline and AI platformThe company’s focus will be on progressing the clinical validation of its idiopathic pulmonary fibrosis treatment.
Alongside new steps in its therapeutic pipeline—and a new push into laboratory robotics—Insilico Medicine has raised $110 ...
Insilico Medicine Inc. is considering an initial public offering after securing funding at a valuation of more than $1 ...
Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced today that it has successfully secured a $110 million Series E ...
DeepSeek’s artificial intelligence breakthrough is stirring up China’s venture capital world after three straight years of ...
Insilico Medicine, a clinical-stage biotechnology company pioneering generative AI for drug discovery and development, ...
Rentosertib is designed to treat IPF by targeting Traf2- and NCK-interacting kinase (TNIK), a serine/threonine kinase whose activation plays a crucial role in cellular processes that include signal ...
8d
News-Medical.Net on MSNInsilico Medicine's AI-driven drug Rentosertib receives official generic nameInsilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, recently announced that its breakthrough drug candidate for idiopathic pulmonary ...
Insilico Medicine has raised $110 million in Series E funding for its artificial intelligence-powered drug discovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results